353 related articles for article (PubMed ID: 9731499)
1. Allogeneic cell therapy for a murine mammary carcinoma.
Morecki S; Yacovlev E; Diab A; Slavin S
Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
[TBL] [Abstract][Full Text] [Related]
2. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
3. Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother (1991); 2001 Mar; 24(2):114-121. PubMed ID: 11449067
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
7. Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer.
Panigrahi S; Yacovlev E; Gelfand Y; Schuger L; Slavin S; Morecki S
Cytokines Cell Mol Ther; 2002; 7(3):99-106. PubMed ID: 12850809
[TBL] [Abstract][Full Text] [Related]
8. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
[TBL] [Abstract][Full Text] [Related]
9. An immune response against the alloantigens of the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts.
Isakov N; Feldman M; Segal S
Invasion Metastasis; 1982; 2(1):12-32. PubMed ID: 6765248
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
11. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
[TBL] [Abstract][Full Text] [Related]
13. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
14. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
15. Growth and metastasis in allogeneic hosts. Lack of H-2-negative or somatic hybrid variant selection.
De Giovanni C; Lollini PL; Nicoletti G; Del Re B; Scotlandi K; Prodi G; Nanni P
Exp Clin Immunogenet; 1987; 4(3):153-62. PubMed ID: 3273420
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
17. Lung colonization and metastasis of murine mammary tumors: relationship to various characteristics of the primary tumors.
Basolo F; Toniolo A; Fontanini G; Squartini F
Invasion Metastasis; 1987; 7(5):275-83. PubMed ID: 3679742
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Anderson LD; Petropoulos D; Everse LA; Mullen CA
Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
[TBL] [Abstract][Full Text] [Related]
19. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
Clark DA; Gorczynski RM; Blajchman MA
Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
[TBL] [Abstract][Full Text] [Related]
20. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI.
Kummar S; Ishii A; Yang HK; Venzon DJ; Kim SJ; Gress RE
Biol Blood Marrow Transplant; 2001; 7(1):25-30. PubMed ID: 11215695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]